EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Can clinicians predict individual patient outcomes in neuroendocrine tumors treated with [177Lu]Lu-DOTATATE?

Javier López-Robles iD, Mercedes Mitjavila iD, Paula Jimenez-Fonseca iD, Isabel Marín-Melero iD, Pilar Belló, Virginia Pubul iD, Amparo Garcia-Burillo iD, Jorge Hernando, Belén Llana, Julián Ardila, Javier Arbizu, Rocío Valverde und 12 weitere

The Oncologist · 06.06.2026 · 31 (7)

DOI: 10.1093/oncolo/oyag231 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Oncologist, online erschienen am 15.06.2026. Verfasst von Javier López-Robles und 23 weiteren Autor:innen. Beteiligte Einrichtung: Medical Oncology Department, Hospital Universitario Morales Meseguer, University de Murcia, IMIB, Murcia, 30008, Spain. Hauptthemen laut MEDLINE: Neuroendocrine Tumors, Octreotide, Organometallic Compounds. Die Arbeit nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Novartis.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Peptide receptor radionuclide therapy (PRRT) has become a cornerstone in the management of neuroendocrine tumors (NETs), yet optimal sequencing and patient selection remain unsettled. This study aimed to develop and internally validate the NEPTUNE score to predict progression-free survival (PFS) in advanced NETs patients receiving [177Lu]Lu-DOTATATE. Materials and Methods Real-world data from the nationwide SEPTRALU registry and the Jules Bordet Institute included patients with advanced NETs treated with [177Lu]Lu-DOTATATE. Predictors of PFS were identified using an accelerated failure time model and combined into the NEPTUNE score. Internal validation was performed using bootstrap resampling. This tool was subsequently transformed into a nomogram and an interactive web-based calculator to enhance its integration into routine clinical practice.

Results

The cohort comprised 647 patients with diverse NET subtypes: pancreatic (39%), midgut (30%), bronchopulmonary (9%), pheochromocytoma/paraganglioma (3%), other gastroenteropancreatic (11%), and other non-gastroenteropancreatic (8%). The NEPTUNE score incorporates ten routinely available variables: ECOG performance status, PRRT line, Ki67 index, number of metastatic sites, primary tumor site, sex, Krenning grade, surgical resection of metastases, presence of liver metastases, and time from advanced tumor diagnosis to PRRT. The score demonstrated strong performance, with an Integrated Brier Score of 0.201 and a bias-corrected C-index of 0.702, indicating good calibration and discrimination.

Conclusions

The NEPTUNE score is a promising tool for predicting individual PFS in patients with advanced NETs treated with [177Lu]Lu-DOTATATE. By integrating readily available clinical variables, it may support clinical decision-making. However, external validation is required before broader clinical implementation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Neuroendocrine TumorsOctreotideOrganometallic CompoundsHumansFemaleMaleMiddle AgedAgedAdultPrognosisNomogramsRadiopharmaceuticals

Stichwörter der Autor:innen

[177Lu]Lu-DOTATATEneuroendocrine tumorsnomogrampeptide receptor radionuclide therapyprognosisprogression-free survival

Substanzen

OctreotideOrganometallic Compoundslutetium Lu 177 dotatateRadiopharmaceuticals

Autor:innen und Institutionen

  • Medical Oncology Department, Hospital Universitario Morales Meseguer, University de Murcia, IMIB, Murcia, 30008, Spain.
  • Nuclear Medicine Department, Hospital Universitario Puerta de Hierro, Majadahonda, 28222, Spain.
  • Medical Oncology Department, Hospital Universitario Central de Asturias, ISPA, Oviedo, 33011, Spain.
  • Nuclear Medicine Department, Institute Jules Bordet, Brussels, 1070, Belgium.
  • Nuclear Medicine Department, Hospital Universitario La Fe, Valencia, 46026, Spain.
  • Nuclear Medicine Department, Hospital Clínico Universitario de Santiago, Santiago de Compostela, 15706, Spain.

ORCID-Profile: Javier López-Robles, Mercedes Mitjavila, Paula Jimenez-Fonseca, Isabel Marín-Melero, Virginia Pubul, Amparo Garcia-Burillo

Förderung

  • Novartis

Zitieren

APA

López-Robles, J., Mitjavila, M., Jimenez-Fonseca, P., Marín-Melero, I., Belló, P., Pubul, V., Garcia-Burillo, A., Hernando, J., Llana, B., Ardila, J., Arbizu, J., Valverde, R., Velasco, M., Castellón, M., Alonso-Gordoa, T., García-Cañamaque, L., Cano, J. M., Tabuenca, M. J., Riesco, M. C., …, & Carmona-Bayonas, A. (2026). Can clinicians predict individual patient outcomes in neuroendocrine tumors treated with [177Lu]Lu-DOTATATE?. The Oncologist, 31(7). https://doi.org/10.1093/oncolo/oyag231

Vancouver

López-Robles J, Mitjavila M, Jimenez-Fonseca P, Marín-Melero I, Belló P, Pubul V, et al. Can clinicians predict individual patient outcomes in neuroendocrine tumors treated with [177Lu]Lu-DOTATATE?. The Oncologist. 2026;31(7). doi:10.1093/oncolo/oyag231

BibTeX
@article{LpezRobles2026,
  author = {López-Robles, Javier and Mitjavila, Mercedes and Jimenez-Fonseca, Paula and Marín-Melero, Isabel and Belló, Pilar and Pubul, Virginia and Garcia-Burillo, Amparo and Hernando, Jorge and Llana, Belén and Ardila, Julián and Arbizu, Javier and Valverde, Rocío and Velasco, Mónica and Castellón, Maribel and Alonso-Gordoa, Teresa and García-Cañamaque, Lina and Cano, Juana María and Tabuenca, María Josefa and Riesco, María Carmen and Custodio, Ana Belén and Piñeiro, Adrián and Balaguer-Muñoz, David and Nevares, Marina and Carmona-Bayonas, Alberto},
  title = {Can clinicians predict individual patient outcomes in neuroendocrine tumors treated with [177Lu]Lu-DOTATATE?},
  journal = {The Oncologist},
  year = {2026},
  volume = {31},
  number = {7},
  doi = {10.1093/oncolo/oyag231}
}
Kostenlos starten →